The COVID-19 vaccine from Oxford University and AstraZeneca is safe, and the primary findings of the two-phase primary, published in the Lancet Thursday show, produce aging-resistant responses.
Why it’s important: Coronavirus cases in the U.S. And growing all over the world. Findings from a study of 560 healthy adults, including 240 people over the age of 70, follow Pfizer’s announcement on Wednesday that his vaccine is 95% effective and Moderna figures released on Monday show that he has a 94.5% vaccination success rate.
Note: The study authors found that the vaccine had few side effects and that “volunteers in the trial showed similarly ineffective antibody titers, and T cell responses in all three age groups (18-55, 56-79, and 70+).”
What they are saying: “Bringing strong immune responses in older adults has been a long-standing challenge,” said Angela Minassian, an investigator at Oxford University, in a statement.
- “To show this vaccine technique is able to induce these responses, in the age group, the highest risk of severe COVID-19 disease, hopefully the vaccine efficacy will be the same in younger and older adults as well.”
What’s next: The results of the three phases of the vaccine, which are ongoing, are expected next week to determine its effectiveness.
Documents by Cloud, read the findings:
Flashback: The World’s Leading Ox Oxford Coronavirus Vaccine Produces Immune Reaction
.
